Munich Cancer Registry



- Baseline statistics
- Selection Matrix
- Homepage

Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany

http://www.tumorregister-muenchen.de/en

Cancer statistics: Survival

Year of diagnosis 1988-1997 1998-2011 1978-1987 Patients 165 456 3,042 456 3,044 Diseases 165 04/01/2013 Creation date 01/03/2013 Export date Population 4.5 m



http://www.tumorregister-muenchen.de/en/facts/surv/surv_C8890E.pdf

C88,C90: Immunoprolif. disease




Figure 1a. Relative survival of patients with immunoprolif. disease by period of diagnosis. Included in the evaluation are 1,813 cases diagnosed between 1978 and 2011.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 1998 to 2009, and are represented by green diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided populationbased statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

Period of diagnosis						
	1978-	1987	1988-	1997	199	98+
	n=1	152	n=3	885	n=1,	276
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0
1	88.2	89.6	88.0	90.2	78.2	80.4
2	73.7	76.4	74.2	77.8	63.1	66.4
3	59.1	62.3	62.4	67.0	54.3	58.5
4	47.7	51.3	54.2	59.6	46.3	51.2
5	44.4	48.4	47.7	53.6	37.8	42.6
6	39.6	44.0	41.1	47.3	32.4	37.3
7	35.6	40.2	36.1	42.3	27.9	32.9
8	32.9	38.0	32.7	39.2	24.6	29.6
9	27.6	32.2	29.8	36.2	20.4	24.8
10	25.5	30.1	26.6	33.3	17.2	21.6

Table 1b. Observed (obs.) and relative (rel.) survival of patients with immunoprolif. disease by period of diagnosis for period 1978-2011 (N=1,813).




Figure 2a. Survival of patients with immunoprolif. disease by gender. Included in the evaluation are 1,661 cases diagnosed between 1988 and 2011.

	Gender							
	Ma	ale	Female					
	n=8	896	n=765					
Years	obs. %	rel. %	obs. %	rel. %				
0	100.0	100.0	100.0	100.0				
1	81.9	84.3	79.0	80.8				
2	68.1	72.0	63.1	66.0				
3	59.3	64.3	52.7	56.3				
4	50.9	56.6	45.3	49.2				
5	43.0	48.9	37.7	41.9				
6	37.0	43.2	32.2	36.6				
7	34.2	40.8	25.9	29.8				
8	31.1	38.2	22.5	26.5				
9	28.0	34.8	19.4	23.1				
10	23.9	30.8	18.0	21.8				

Table 2b. Observed (obs.) and relative (rel.) survival of patients with immunoprolif. disease by gender for period 1988-2011 (N=1,661).






Figure 2c. Conditional relative 2 / 5-year survival of patients with immunoprolif. disease by gender. For 1,661 of 1,661 cases diagnosed between 1988 and 2011 valid data could be obtained for this item.

		G	Gender	•			
		Male		F	emale		
		Cond. s	urv. %	Cond. surv. %			
Years	n	2 yrs	5 yrs	n	2 yrs	5 yrs	
0	896	72.0	48.9	765	66.0	41.9	
1	682	76.3	51.4	562	69.7	45.4	
2	520	78.9	56.9	415	74.6	45.4	
3	405	76.2	59.7	317	74.7	47.4	
4	310	76.6	62.0	244	74.5	47.3	
5	232	83.6	63.4	179	71.5	52.4	
6	177	88.8	63.7	133	72.8	58.3	
7	149	85.7	61.9	97	77.8	64.4	
8	128	81.1	58.9	77	82.5	63.6	
9	99	78.0	60.5	59	91.4	66.1	
10	77	81.6	64.7	50	87.6	63.0	

Table 2d. Conditional relative 2 / 5-year survival of patients with immunoprolif. disease by gender for period 1988-2011 (N=1,661).

Conditional relative survival rates refer to the relative survival probability, in this case for 2 and 5 years after cancer diagnosis, compared to the age- and sex-matched population (=100%) under the condition of being alive for a certain time period (x-axis in Figure 2a). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup gender="Male", who are alive at least 3 years after cancer diagnosis, the conditional relative 2-year survival rate is 76.2% (n=405).




Figure 3a. Relative survival of patients with immunoprolif. disease by age category. Included in the evaluation are 1,661 cases diagnosed between 1988 and 2011.

Age category										
0-49 yrs		50-59 yrs		60-69 yrs		70-79 yrs		80+ yrs		
	n=150		n=310		n=525		n=480		n=196	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	94.6	94.3	89.5	89.9	85.7	86.9	73.1	75.7	59.1	64.5
2	87.1	87.1	80.3	81.1	70.9	73.1	54.5	58.7	38.0	45.4
3	80.6	80.5	71.8	73.4	61.9	64.8	44.4	49.8	23.6	31.7
4	73.5	74.4	68.2	70.0	51.5	54.9	34.9	41.2	16.6	24.7
5	66.5	67.4	60.7	63.1	41.4	45.0	29.2	36.4		
6	61.2	61.7	52.9	55.5	36.4	40.5	22.7	30.0		
7	60.0	60.3	47.4	50.0	30.9	35.2	17.4	24.3		
8	57.5	58.1	44.0	47.1	28.2	33.0	12.2	18.1		
9	53.3	53.6	40.3	43.0	23.6	28.3	10.5	16.3		
10	47.4	47.7	37.4	40.6	21.9	27.0				

Table 3b. Observed (obs.) and relative (rel.) survival of patients with immunoprolif. disease by age category for period 1988-2011 (N=1,661).






Figure 5a. Observed post-progression survival of 834 patients with immunoprolif. disease diagnosed between 1978 and 2011 (incl. M1). These 834 patients with documented progression events during their course of disease represent 46.0% of the totally 1,813 evaluated cases. Patients with cancer relapse documented via death certificates only were excluded (n=314, 17.3%).

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement "not specified" is the only information in registries regarding relapse of the disease. The category "All types" denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100% value because patients are potientially considered in more than one subgroup.

Type of progression					
All types					
	n=834				
Months	%				
0	100.0				
12	64.9				
24	48.8				
36	39.2				
48	33.1				
60	27.4				

Table 5b. Observed post-progression survival of patients with immunoprolif. disease for period 1978-2011 (N=834).

Shortcuts

AS Assembled survival chart (observed, expected, relative) CS Conditional survival DCO Death certificate only. The death certificate provides the only notification to the registry. Munich Cancer Registry, Germany (Tumorregister München) MCR NA Not available NCI National Cancer Institute, USA NOS Not otherwise specified Observed/overall survival (Kaplan-Meier estimate) OS PPS Post-progression survival RS Relative Survival. Ratio of observed and expected survival (derived from the normal population) SEER Surveillance, Epidemiology, and End Results, USA TTP Time to progression Date of entry: Date of diagnosis Event (Progression): First local recurrence, lymph node relapse or distant metastasis, unspecified recurrence First all-cause recurrence is illustrated by survival curves (Kaplan-Meier estimate). First local recurrence, lymph node relapse or distant metastasis are depicted cumulatively, where applicable ("reverse" Kaplan-Meier estimate). UICC Union for International Cancer Control, Geneva

Recommended Citation

Munich Cancer Registry. Survival C88,C90: Immunoprolif. disease [Internet]. 2013 [updated 2013 Apr 1; cited 2013 May 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/surv/surv_C8890E.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Munich Cancer Registry

Index of figures and tables

Fig./Tbl.	Page
1a Relative survival by period of diagnosis (chart)	2
1b Survival by period of diagnosis (table)	2
2a Survival by gender (chart)	3
2b Survival by gender (table)	3
2c Conditional survival by gender (chart)	4
2d Conditional survival by gender (table)	4
3a Relative survival by age category (chart)	5
3b Survival by age category (table)	5
5a Observed post-progression survival (chart)	6
5b Observed post-progression survival (table)	6

Munich Cancer Registry